Alpha Tau Medical (NASDAQ:DRTS) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says

Alpha Tau Medical (NASDAQ:DRTS) had its price objective increased by stock analysts at LADENBURG THALM/SH SH from $12.00 to $14.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 41.70% from the stock’s previous close.

DRTS has been the subject of several other research reports. Piper Sandler restated a “neutral” rating and issued a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Citigroup raised their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Finally, HC Wainwright raised their target price on Alpha Tau Medical from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Alpha Tau Medical presently has an average rating of “Hold” and a consensus price target of $10.75.

Alpha Tau Medical Stock Performance

Shares of DRTS stock traded down $0.46 on Tuesday, hitting $9.88. 872,370 shares of the stock were exchanged, compared to its average volume of 428,413. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $869.54 million, a PE ratio of -18.64 and a beta of 1.11. Alpha Tau Medical has a one year low of $2.75 and a one year high of $10.80. The firm’s 50 day moving average is $7.43 and its two-hundred day moving average is $6.17.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Sell-side analysts expect that Alpha Tau Medical will post -0.5 earnings per share for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Institutional investors and hedge funds have recently modified their holdings of the business. Trifecta Capital Advisors LLC bought a new stake in shares of Alpha Tau Medical in the 4th quarter worth approximately $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the third quarter valued at approximately $62,000. Bank of America Corp DE boosted its position in shares of Alpha Tau Medical by 2,779.1% during the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Alpha Tau Medical by 291.7% during the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of Alpha Tau Medical during the first quarter valued at approximately $132,000. Hedge funds and other institutional investors own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.